Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person13
Moleculin Biotech, Inc.
Company
Edesa Biotech, Inc.
Company
NKGen Biotech, Inc.
Company
XBiotech Inc.
Company
Krystal Biotech, Inc.
Company
Fortress Biotech, Inc.
Company
MAIA Biotechnology, Inc.
Company
GOLDENWELL BIOTECH, INC.
Company
ONCOLYTICS BIOTECH INC
Company
PharmaCyte Biotech, Inc.
Company
Vir Biotechnology, Inc.
Company
PUMA BIOTECHNOLOGY, INC.
Company
Sana Biotechnology, Inc.
Company
Primary record17
Moleculin Biotech, Inc. filed 4
SEC form 4 filed by Moleculin Biotech, Inc. (CIK 1659617) on 2026-11-06.
Moleculin Biotech, Inc. filed 4
SEC form 4 filed by Moleculin Biotech, Inc. (CIK 1659617) on 2026-11-06.
Moleculin Biotech, Inc. filed 4
SEC form 4 filed by Moleculin Biotech, Inc. (CIK 1659617) on 2026-11-06.
Moleculin Biotech, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure On November 4, 2026, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced that an abstract highlighting data from its lead drug candidate, Annamycin, has been
Moleculin Biotech, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure On October 30, 2026, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial eval
Moleculin Biotech, Inc. filed 8-K
Item 3.03. Material Modifications of Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 herein is incorporated by reference into this Item 3.03. Item 5.03
Moleculin Biotech, Inc. filed 4
SEC form 4 filed by Moleculin Biotech, Inc. (CIK 1659617) on 2026-10-16.
Moleculin Biotech, Inc. filed 4
SEC form 4 filed by Moleculin Biotech, Inc. (CIK 1659617) on 2026-10-16.
Moleculin Biotech, Inc. filed 4
SEC form 4 filed by Moleculin Biotech, Inc. (CIK 1659617) on 2026-10-16.
Moleculin Biotech, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure On October 16, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibi
Moleculin Biotech, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As reported below under Item 5.07 of this Current Report, Molec
Moleculin Biotech, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure On October 5, 2026, Moleculin Biotech, Inc. (the Company ) is using the attached presentation for its corporate presentation posted on the Company s website and is set forth as Exhibit
Moleculin Biotech, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure On September 29, 2026, Moleculin Biotech, Inc. (the Company ), issued a press release which announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRA
Moleculin Biotech, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure On June 30, 2026, Moleculin Biotech, Inc. (the Company ), issued a press release which announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also kno
Moleculin Biotech, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure On September 25, 2026, Moleculin Biotech, Inc. (the Company ), issued a press release which announced new preclinical data indicating that the antitumor activity of its lead drug candid
Moleculin Biotech, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure On September 23, 2026, Moleculin Biotech, Inc. (the Company ), issued a press release which announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening
Moleculin Biotech, Inc. filed 8-K
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 15, 2026, Moleculin Biotech, Inc. (the Company ) received a letter (the Staff Determination Lett